RxDoctor Payments Data

Anubhav Garg, MD

Cardiovascular Disease · Akron, OHNPI 1427175322

Payments from drug & device makers

$427in general payments, 2019–2025

Across 10 payments — averaging $42.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$125
  • Abbott$96
  • Pfizer$86
  • Bayer$39
  • Merck$23
  • Scpharmaceuticals Inc.$18
  • plus $41 from 3 others

What the payments were for

  • Speaking & faculty fees$12529%
  • Food & beverage$30271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi1$125
Abbott1$96
Pfizer1$86
Bayer2$39
Merck1$23
Scpharmaceuticals Inc.1$18
Novartis1$16
Abiomed1$13
Johnson & Johnson1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$427 in reported general payments places this provider in the 25th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$82,759
Medicare patients
1,051
Services billed
1,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$402,143
JardianceEmpagliflozin193$226,032
EntrestoSacubitril/Valsartan103$129,930
FarxigaDapagliflozin Propanediol57$61,502
XareltoRivaroxaban56$57,303
Repatha SureclickEvolocumab45$39,079
NexletolBempedoic Acid12$13,217
JanuviaSitagliptin Phosphate12$6,036
Praluent PenAlirocumab11$5,378
Metoprolol Succinate409$4,875
MyrbetriqMirabegron12$4,850
Atorvastatin Calcium487$4,038
Ranolazine ErRanolazine22$3,099
Ezetimibe102$2,706
Rosuvastatin Calcium188$1,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$402,143324 claims
NovartisEntresto$16$129,930103 claims
Johnson & JohnsonXarelto$11$57,30356 claims
MerckJanuvia$23$6,03612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →